Pharmaceuticals, Biotechnology & Life Sciences

Insider selling at Alector Inc. shows a planned 10b5‑1 strategy—executive sales amid a 29% price surge—highlighting potential liquidity moves and future funding signals.

Insider activity at Cronos Group shows executives buying common shares and holding RSUs, signaling confidence in the company’s cannabis‑market growth and long‑term value.

Insider buying by Iovance’s COO signals confidence amid rising stock and strong clinical progress—what it means for investors.

Vir Biotechnology’s insider buying surge signals confidence in a new PSMA‑targeting partnership and earnings beat, hinting at future upside.

Corcept insider Wilson buys 100,000 shares amid earnings miss and regulatory hurdles, signaling cautious confidence in its Cushing’s drug pipeline.

Discover why United Therapeutics’ leadership is buying and selling shares at strategic times—insider moves reveal confidence in a growing vascular therapy pipeline and solid long‑term upside.

Supernus CFO’s 2,500‑share buy after an RSU sale signals confidence, boosting investor optimism amid a volatile, growth‑oriented biotech pipeline.

Beam Therapeutics’ President Giuseppe Ciaramella’s recent trades—buying at $17, selling at $32, and liquidating options—signal confidence, disciplined risk‑management, and a bullish outlook for the gene‑therapy company’s future.

Quantum‑Si insider buy by senior owner Jafri Amir signals renewed confidence amid sales, hinting at a potential shift toward growth and higher valuation.

Tonix insiders buying zero‑cost options shows confidence in future gains; learn how this move signals upside and what it means for investors.